Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Rezetecan +/- Bevacizumab in BLIS TNBC
NCT07669610Phase 3Not yet recruiting
- Sponsor
- Fudan University
- Start
- Oct 2026
- Primary completion
- Sep 2028
01
Overview
A Phase 3 trial of trastuzumab rezetecan, bevacizumab in triple-negative breast cancer (TNBC), sponsored by Fudan University. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
trastuzumab rezetecanbevacizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT07669610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07669610.